Question from Deputy Ken O'Flynn - PQ 15879-26
Deputy O'Flynn asked about the budget impact analysis in respect of the proposed reimbursement of tirzepatide and semaglutide for diabetes and weight management
- Published date:
- :
Browse and read HSE's latest publications, which include strategic plans, reports, official policies and codes, Parliamentary Question (PQ) responses, and board meeting minutes.
Deputy O'Flynn asked about the budget impact analysis in respect of the proposed reimbursement of tirzepatide and semaglutide for diabetes and weight management
Deputy O'Flynn asked about the full health technology assessment of tirzepatide type 2 diabetes mellitus and for weight management. Read the HSE response.
Deputy O'Flynn asked about the full health technology assessment of tirzepatide for type 2 diabetes. Read the HSE response.
Deputy O'Flynn asked about the pharmacoeconomic evaluations of tirzepatide and semaglutide. Read the HSE response.
Deputy O'Flynn asked about the reimbursement of tirzepatide for weight management. Read the HSE response.
Deputy O'Flynn asked about the health technology assessments conducted in respect of tirzepatide. Read the HSE response.
Deputy O'Flynn asked about the use of tirzepatide for type 2 diabetes mellitus and weight management. Read the HSE response.
Deputy Daly asked about emergency caesarean sections carried out at University Hospital Kerry. Read the HSE response.
Deputy Daly asked for an update on the maternity and neonatal unit project at University Hospital Kerry. Read the HSE response.
Deputy Daly asked for an update on the proposed new maternity hospital development at University Hospital Kerry. Read the HSE response.